STOK · Company research
Stoke Therapeutics, Inc. Common Stock (STOK): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics: The Market Misread A Key FDA Win (NASDAQ:STOK) - Seeking Alpha | Stoke Therapeutics: The Market Misread A Key FDA Win (NASDAQ:STOK) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 19, 2026 | neutral | 0 | 0.6 |
| STOK Nov 2026 20.000 put (STOK261120P00020000) Stock Historical Prices & Data - Yahoo! Finance Canada | STOK Nov 2026 20.000 put (STOK261120P00020000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 18, 2026 | neutral | 0 | 0.6 |
| STOK Nov 2026 20.000 put (STOK261120P00020000) stock historical prices and data - Yahoo Finance Australia | STOK Nov 2026 20.000 put (STOK261120P00020000) stock historical prices and data Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 18, 2026 | neutral | 0 | 0.6 |
| Assenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat | Assenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOK MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25 - MarketBeat | Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25 MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| A new CIO received options on 70,000 shares at Stoke Therapeutics. 17 new hires got grants too. - Stock Titan | A new CIO received options on 70,000 shares at Stoke Therapeutics. 17 new hires got grants too. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Liquidity Mapping Around (STOK) Price Events - Stock Traders Daily | Liquidity Mapping Around (STOK) Price Events Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 15, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell? - MarketBeat | Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell? MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| STOK: Stoke Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | STOK: Stoke Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| How FDA Filing Clarity At Stoke Therapeutics (STOK) Has Changed Its Investment Story - Simply Wall Street | How FDA Filing Clarity At Stoke Therapeutics (STOK) Has Changed Its Investment Story Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us | Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Oct 2026 $STOK - MarketBeat | Stoke Therapeutics (STOK) Short Interest & Short Float | Updated Oct 2026 $STOK MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| An inherited eye disease can cause irreversible vision loss. Stoke expects initial trial data in the first half of 2027. - Stock Titan | An inherited eye disease can cause irreversible vision loss. Stoke expects initial trial data in the first half of 2027. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| (STOK) Risk Channels and Responsive Allocation - Stock Traders Daily | (STOK) Risk Channels and Responsive Allocation Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 5, 2026 | neutral | 0 | 0.6 |
| STOK Nov 2026 30.000 put (STOK261120P00030000) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada | STOK Nov 2026 30.000 put (STOK261120P00030000) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 3, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock - MarketBeat | Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK). - Stock Titan | At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK). Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK). - Stock Titan | Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK). Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares - MarketBeat | Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| Stoke Therapeutics (STOK) Stock May Be Fully Priced On Pipeline Hopes - Simply Wall Street | Stoke Therapeutics (STOK) Stock May Be Fully Priced On Pipeline Hopes Simply Wall Street | View source ↗ | Simply Wall Street | Sep 8, 2026 | neutral | 0 | 0.6 |
| What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Yahoo Finance | What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 7, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.